Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals Incorporated    VRTX

Delayed Quote. Delayed  - 09/29 10:00:01 pm
85 USD   -4.32%
04:58p VERTEX PHARMACE : VRTX): Get In While Markets Look The Other Way
09/28 VERTEX PHARMACE : U.S. Food and Drug Administration Approves ORKAMBI..
09/22 NASDAQ 100 MOVE : Bmrn, bbby
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Vertex Pharmaceuticals Incorporated : VRTX, OSTK, and GRPN added to Nasdaq Gainers Watch List at GSR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/19/2013 | 05:40pm CEST

New York, NY -- (ACCESSWIRE) -- 04/19/2013 -- Growing Stock Report initiates a NASDAQ Gainers Weekly Watch List adding Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Overstock.com Inc. (NASDAQ:OSTK), Groupon, Inc. (NASDAQ:GRPN), BioScrip Inc. (NASDAQ:BIOS) and Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX).

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) a company that engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases is currently up (+55.57%) on 13,455,455 shares traded after announcing statistically significant results from a phase 2 study for the treatment of cystic fibrosis. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is currently up (+134.49%) from its recent 52-week low which has prompted Growing Stock Report to add the stock to their NASDAQ Gainers Watch List.

To see what other Investors are saying about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=VRTX&SubId=AW

Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) a development-stage specialty pharmaceutical company is currently up (+24.10%) on 1,789,829 shares traded after Coverage was initiated on Catalyst Pharmaceutical by Aegis Capital. Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) is currently up (+105.41%) from its recent 52-week low which has prompted Growing Stock Report to add the stock to their NASDAQ Gainers Watch List.

To see what other Investors are saying about Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=CPRX&SubId=AW

Also mentioned in Growing Stock Report's Nasdaq Gainers Watch List and Investor Poll was: Overstock.com Inc. (NASDAQ:OSTK), Groupon, Inc. (NASDAQ:GRPN), Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) and BioScrip Inc. (NASDAQ:BIOS).

To see what other Investors are saying about: OSTK, GRPN, CPRX and BIOS

Click Here: http://www.growingstockreport.com/PR.aspx?stock=OSTK-GRPN-CPRX-BIOS&SubID=AW

GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.GrowingStockReport.com

Disclosure: GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.

Contact Info:
Growing Stock Report
editor@GrowingStockReport.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VERTEX PHARMACEUTICALS INC
04:58p VERTEX PHARMACEUTICALS INCORPORATED : VRTX): Get In While Markets Look The Othe..
09/28 VERTEX PHARMACEUTICALS INCORPORATED : U.S. Food and Drug Administration Approves..
09/22 NASDAQ 100 MOVERS : Bmrn, bbby
09/20 New Crystallization Development Methods Revealed in On-Demand Webinars from M..
09/19 New Crystallization Development Methods Revealed in On-Demand Webinars from M..
09/16 NASDAQ 100 MOVERS : Expe, wdc
09/15 VERTEX PHARMACEUTICALS INCORPORATED : Investigators at Vertex Pharmaceuticals In..
09/15 VERTEX PHARMACEUTICALS INCORPORATED : Researchers from Vertex Pharmaceuticals In..
09/15 VERTEX PHARMACEUTICALS INCORPORATED : Patent Issued for Solid Forms of 3-(6-(1-(..
09/15 VERTEX PHARMACEUTICALS INCORPORATED : to Present at Upcoming Investor Conference..
More news
Sector news : Bio Therapeutic Drugs
03:37pDJARROWHEAD PHARMACEUTICALS : Amgen, Arrowhead Pharma Agree to Cardiovascular Coll..
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
09/28 FDA approves expanded use of Vertex's CF drug Orkambi; 2016 revenue guidance ..
09/22 Biotech ETF IBB Could Get A Boost From A Potential Gilead Merger Or Acquisiti..
09/19 Sarepta to charge $300K for yearly course of Exondys 51
09/16 Healthcare ratings roundup - new coverage
09/15 Will The FDA Approve A Label Expansion For Vertex's Blockbuster Cystic Fibros..
Advertisement
Financials ($)
Sales 2016 1 751 M
EBIT 2016 254 M
Net income 2016 -56,9 M
Finance 2016 338 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017 50,98
EV / Sales 2016 12,4x
EV / Sales 2017 8,57x
Capitalization 22 013 M
More Financials
Chart VERTEX PHARMACEUTICALS INC
Duration : Period :
Vertex Pharmaceuticals Inc Technical Analysis Chart | VRTX | US92532F1003 | 4-Traders
Full-screen chart
Technical analysis trends VERTEX PHARMACEUT...
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 110 $
Spread / Average Target 24%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Simon Bedson SVP & GM-International Commercial Operations
Ian F. Smith Chief Financial Officer & Executive Vice President
Jeffrey A. Chodakewitz Chief Medical Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS..-29.40%22 013
AMGEN, INC.4.55%127 004
GILEAD SCIENCES, INC.-21.96%104 213
CELGENE CORPORATION-11.63%82 030
REGENERON PHARMACEUTIC..-22.80%44 129
ACTELION LTD19.91%18 841
More Results